THE ABILITY of a series of human lung carcinoma xenografts to predict clinical response to cytotoxic drugs was demonstrated by Shorthouse et al. (1980) when tumour biopsy samples from patients with lung cancer were established as xenografts in immune-suppressed mice and the drug combinations used to treat the patients were also administered to the xenograftbearing mice. Tumour-growth delay in the xenografts correlated closely with the clinical tumour response in the patients.
That study suggested that these lung tumour xenografts might be useful in comparing the efficacy of new drug analogues with the parent drugs. Vindesine is a new Vinca alkaloid, derived from vinblastine and closely related to vincristine. Phase II clinical trials suggest that vindesine has activity against small-cell and adenocarcinoma of the lung (Natale et al., 1980; Mattson et al., 1980) . Its clinical efficacy has not been compared with that of vincristine, however. The anti-tumour effect of vindesine was therefore compared with vincristine in 4 lungcarcinoma xenografts.
Female CBA/lac mice were immunesuppressed by neonatal thymectomy, followed 2-4 weeks later by 9 Gy whole-body irradiation (Steel et al., 1978) .
The 4 xenograft lines used in these experiments were in early passage (6-12) and had originally been established from human material obtained at biopsy: small-cell xenograft I from a peural metastasis and the other 3 from skin metastases. For each xenograft line, tumour fragments were bilaterally implanted s.c. into the flanks of 8-10-weekold mice, prepared as described above.
When the tumours had reached a volume of 0 3-0'5 cm3 they were ranked according to their volume, calculated by the formula TLD2/6, where L is the longest diameter and D is the diameter at right angles to it (Cobb & Mitchley, 1974) and allocated to treatment or control groups. Each group contained about 12 tumours of similar volume to those in the other groups. Histology and chromosome analysis, performed on each xenograft line, confirmed their human origin.
Drugs were made up in normal saline, and groups of mice were then treated with a single i.p. bolus injection of vincristine sulphate (Oncovin-Eli Lilly) at a dose of 1 2 mg/kg or vindesine sulphate (Eldisine -Eli Lilly) at a dose of 3 0 mg/kg. Due to their known different toxicities (vincristine neurotoxicity; vindesine marrow and neurotoxicity) overall survival rather than target-tissue toxicity was used in assessing equitoxic doses.
The parameter of chemotherapeutic response was the in situ endpoint of growth delay (GD) which was determined by dividing the difference between mean doubling times of control (TD,) and treated tumours (TDt) by TD, GD=TDt-TDc TDThis produced an estimate of growth delay in terms of TDC, equivalent to the doubling times saved (DTS) of Kopper & Steel (1975) .
The actual growth rates were calculated by comparing the tumour volume of every tumour at time t (Vt) with its own volume at the beginning of the experiment (Vo).
The ratio Vt: Vo was then calculated for each tumour at each sampling time, and a mean and standard error were calculated for each treatment group at each sampling time.
In the one case where a tumour went into complete remission (i.e. the tumour disappeared and did not regrow by the end of the experiment) the tumour was excluded from all subsequent growthdelay estimations.
The Mann-Whitney U test was used to perform the statistical analysis. The doubling times of the individual tumours for each group were compared with those of the other groups.
The mortalities produced by the 2 agents in this experiment were very similar: 7/31 mice treated with vindesine and 6/29 mice treated with vincristine died before the end of the experiment. This showed that the ratio of vindesine: vincristine used clinically (5:2) produced equal mortality rates when administered by i.p. injection to immune-suppressed mice.
Comparative tumour growth delays for vindesine and vincristine are given in the Table. For both small-cell carcinoma studies in the clinic. These results suggest that vindesine might be worth comparing with the parent compound vincristine in combination chemotherapy for small-cell lung cancer. Similar xenograft studies might also be used for the preclinical assessment of other new agents and analogues.
